SEARCH

SEARCH BY CITATION

References

  • 1
    Bieche I, Narjoz C, Asselah T, Vacher S, Marcellin P, Lidereau R, Beaune P & de Waziers I (2007) Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genomics 17, 731742.
  • 2
    Su T, Bao ZP, Zhang QY, Smith TJ, Hong JY & Ding XX (2000) Human cytochrome p450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res 60, 50745079.
  • 3
    Zhu LR, Thomas PE, Lu G, Reuhl KR, Yang GY, Wang LD, Wang SL, Yang CS, He XY & Hong JY (2006) CYP2A13 in human respiratory tissues and lung cancers: an immunohistochemical study with a new peptide-specific antibody. Drug Metab Dispos 34, 16721676.
  • 4
    Fukami T, Katoh M, Yamazaki H, Yokoi T & Nakajima M (2008) Human cytochrome P450 2A13 efficiently metabolizes chemicals in air pollutants: naphthalene, styrene, and toluene. Chem Res Toxicol 21, 720725.
  • 5
    Porubsky PR, Meneely KM & Scott EE (2008) Structures of human cytochrome P-450 2E1. Insights into the binding of inhibitors and both small molecular weight and fatty acid substrates. J Biol Chem 283, 3369833707.
  • 6
    Porubsky PR, Battaile KP & Scott EE (2010) Human cytochrome P450 2E1 structures with fatty acid analogs reveal a previously unobserved binding mode. J Biol Chem 285, 2228222290.
  • 7
    Smith BD, Sanders JL, Porubsky PR, Lushington GH, Stout CD & Scott EE (2007) Structure of the human lung cytochrome P450 2A13. J Biol Chem 282, 1730617313.
  • 8
    Yano JK, Hsu MH, Griffin KJ, Stout CD & Johnson EF (2005) Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen. Nat Struct Mol Biol 12, 822823.
  • 9
    Yano JK, Denton TT, Cerny MA, Zhang X, Johnson EF & Cashman JR (2006) Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization. J Med Chem 49, 69877001.
  • 10
    Kimonen T, Juvonen RO, Alhava E & Pasanen M (1995) The inhibition of CYP enzymes in mouse and human liver by pilocarpine. Br J Pharmacol 114, 832836.
  • 11
    Kinonen T, Pasanen M, Gynther J, Poso A, Jarvinen T, Alhava E & Juvonen RO (1995) Competitive inhibition of coumarin 7-hydroxylation by pilocarpine and its interaction with mouse CYP 2A5 and human CYP 2A6. Br J Pharmacol 116, 26252630.
  • 12
    DeVore NM, Smith BD, Urban MJ & Scott EE (2008) Key residues controlling phenacetin metabolism by human cytochrome P450 2A enzymes. Drug Metab Dispos 36, 25822590.
  • 13
    DeVore NM, Smith BD, Wang JL, Lushington GH & Scott EE (2009) Key residues controlling binding of diverse ligands to human cytochrome P450 2A enzymes. Drug Metab Dispos 37, 13191327.
  • 14
    Ekroos M & Sjogren T (2006) Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc Natl Acad Sci USA 103, 1368213687.
  • 15
    Williams PA, Cosme J, Ward A, Angove HC, Matak Vinkovic D & Jhoti H (2003) Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 424, 464468.
  • 16
    Leslie AG (2005) The integration of macromolecular diffraction date. Acta Crystallogr D Biol Crystallogr 62, 4857.
  • 17
    Evans P (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50, 760763.
  • 18
    Emsley P & Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60, 21262132.
  • 19
    DeLano WL (2002) The PyMOL Molecular Graphics System. DeLano Scientific, Palo Alto, CA.
  • 20
    Kleywegt GJ, Zou JY, Kjeldgaard M & Jones TA (2001) Chapter 17.1. In: International Tables for Crystallography, F (Rossman MG & Arnold E, eds), pp. 353356, 366–367. Kluwer Academic Publishers, The Netherlands.